Latest News

Could the Omicron surge hasten the transition from pandemic to endemic?


 

A shorter, more intense surge?

The United Kingdom’s experience with COVID-19 has often served as a bellwether of what is likely to happen in the U.S. If that is the case with the Omicron surge, the peak should last about 4 weeks, Dr. Mylonakis said.

In other words, the accelerated spread of Omicron could mean this surge passes more quickly than Delta.

Furthermore, some evidence suggests neutralizing antibodies produced by Omicron infection remain effective against the Delta variant – thereby reducing the risk of Delta reinfections over time.

The ability to neutralize the Delta variant increased more than fourfold after a median 14 days, according to data from a preprint study posted Dec. 27 on MedRxiv.

At the same time, neutralization of the Omicron variant increased 14-fold as participants mounted an antibody response. The study was conducted in vaccinated and unvaccinated people infected by Omicron in South Africa shortly after symptoms started. It has yet to be peer reviewed.

Eric Topol, MD, editor-in-chief of Medscape, described the results as “especially good news” in a tweet.

The current surge could also mean enhanced protection in the future.

“As we look at getting to the other side of this Omicron wave, we will end up with more immunity,” Dr. Madad said. “And with more immunity means we’ll be better guarded against the next emerging variant.”

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

12 state boards have disciplined docs for COVID misinformation
Federal Practitioner
COVID-19 asymptomatic infection rate remains high
Federal Practitioner
COVID-19 and coping with superimposed traumas
Federal Practitioner
BMJ slams ‘incompetent’ Facebook fact-checking of vaccine article
Federal Practitioner
Remdesivir may keep unvaccinated out of the hospital: Study
Federal Practitioner
COVID booster protection may wane in about 10 weeks, new data show
Federal Practitioner
COVID-19–positive or exposed? What to do next
Federal Practitioner
FDA backs Pfizer booster for 12- to 15-year-olds
Federal Practitioner
10 reasons why Omicron could cause big destruction
Federal Practitioner
CDC defends new COVID guidance as doctors raise concerns
Federal Practitioner